Hosted on MSN4d
J&Js Lazcluze/Rybrevant combination obtains European approval to treat NSCLC
The Lazcluze plus Rybrevant combination could challenge AstraZeneca’s standard-of-care Tagrisso in non-small cell lung cancer ...
The Pharma Letter5d
EC approves added use for J&J’s Lazcluze combo with Rybrevant for lung cancer
The European Commission (EC) has approved a Marketing Authorization (MA) for Lazcluze (lazertinib), in combination with ...
precisionmedicineonline3d
J&J Reports Strong Uptake of Carvykti and Rybrevant in Q4
The company's multiple myeloma franchise, which includes Carvykti, stands to contribute significantly to its growth in 2025.
J&J says its lung cancer drug combination keeps people alive longer
Johnson & Johnson said a combination of its lung cancer drugs Rybrevant and Lazcluze kept people alive for at least a year longer than AstraZeneca's Tagrisso in a clinical trial. J&J is trying to ...
pharmaphorum7d
J&J says Rybrevant combo has survival edge over Tagrisso
Johnson & Johnson's recently approved combination of Rybrevant and Lazcluze has improved overall survival compared to AstraZeneca's Tagrisso in a head-to-head trial, claiming what could be a key ...
FiercePharma3d
J&J stands by sales growth ambitions—and points to potential Tremfya boon—as Stelara biosimilars take hold
As Stelara biosimilars chip away at sales in Europe and off-brand rivals start to grace the stage in the U.S., Johnson & ...
Johnson & Johnson’s rybrevant plus lazcluze improve survival in lung cancer
Johnson & Johnson announced positive topline results for the gold standard endpoint in cancer treatment of overall survival, or OS, from ...
Cure Today18d
Rybrevant Plus Lazcluze Improves Survival for EGFR+ NSCLC
Rybrevant and Lazcluze combination therapy improves overall survival in EGFR-mutated NSCLC compared to Tagrisso, as shown in the MARIPOSA study. The FDA approved Rybrevant plus Lazcluze in 2024, based ...